CDC25 phosphatase inhibitors: An update

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 1, 2012, Pages 62-73

  Lavecchia, A ^a   Di Giovanni, C ^a   Novellino, E ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antiproliferative agents; Cancer; CDC25 inhibitors; Cell cycle; Dual specificity phosphatases

Indexed keywords

AMINO ACID; ARGININE; CDC25A PHOSPHATASE; CDC25B PHOSPHATASE; CDC25C PHOSPHATASE; CYCLIN DEPENDENT KINASE; CYSTEINE; ELECTROPHILE; HISTIDINE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINONE DERIVATIVE; REGULATOR PROTEIN; SCAFFOLD PROTEIN; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ALLERGY; ALOPECIA; ALPHA HELIX; AMINO TERMINAL SEQUENCE; AUTOINFLAMMATORY DISEASE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DIVISION; CHICKEN; DEGENERATIVE DISEASE; DNA DAMAGE; DNA REPLICATION; DRUG CONCENTRATION; ENZYME ACTIVE SITE; EUKARYOTIC CELL; GENOMIC INSTABILITY; GRAFT REJECTION; HELA CELL; HIGH THROUGHPUT SCREENING; HUMAN; HYPERACTIVITY; IN VITRO STUDY; LUNG ADENOCARCINOMA; MITOSIS; NONHUMAN; OOCYTE MATURATION; PARASITOSIS; PROSTATE CANCER; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STABILITY; REVIEW; SQUAMOUS CELL CARCINOMA; VULVA CARCINOMA; XENOGRAFT; XENOPUS LAEVIS;

CDC25 PHOSPHATASES; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; ENZYME INHIBITORS; HUMANS; NEOPLASMS;

EID: 84855849159     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712798868940     Document Type: Review

References (82)

1. Fersht, A. Structure and Mechanism in Protein Science. A Guide to Enzyme Catalysis and Protein Folding; W. H. Freeman and Co.: New York, 1999.
2. Fauman, E.B.; Yuvaniyama, C.; Schubert, H.L.; Stuckey, J.A.; Saper, M.A. The X-ray crystal structures of Yersinia tyrosine phosphatase with bound tungstate and nitrate. Mechanistic implications. J. Biol. Chem., 1996, 271(31), 18780-18788.
3. Barford, D. Molecular mechanisms of the protein serine/threonine phosphatases. Trends Biochem. Sci., 1996, 21(11), 407-412.
4. Barford, D.; Das, A.K.; Egloff, M.P. The structure and mechanism of protein phosphatases: insights into catalysis and regulation. Annu. Rev. Biophys. Biomol. Struct., 1998, 27, 133-164.
5. Denu, J.M.; Stuckey, J.A.; Saper, M.A.; Dixon, J.E. Form and function in protein dephosphorylation. Cell, 1996, 87(3), 365-368.
6. Egloff, M.P.; Cohen, P.T.; Reinemer, P.; Barford, D. Crystal structure of the catalytic subunit of human protein phosphatase and its complex with tungstate. J. Mol. Biol., 1995, 254(5), 942-959.
7. Alonso, A.; Sasin, J.; Bottini, N.; Friedberg, I.; Osterman, A.; Godzik, A.; Hunter, T.; Dixon, J.; Mustelin, T. Protein tyrosine phosphatases in the human genome. Cell, 2004, 117(6) 699-711.
8. Lazo, J.S.; Wipf, P. Is Cdc25 a Druggable Target? Anticancer Agents Med. Chem., 2008, 8(8), 837-842.
9. Boudolf, V., Inze, D.; De Veylder, L. What if higher plants lack a CDC25 phosphatase? Trends Plant Sci., 2006, 11(10), 474-479.
10. Galaktionov, K.; Beach, D. Specific activation of Cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell, 1991, 67(6), 1181-1194.
11. Sadhu, K.; Reed, S.I.; Richardson, H.; Russell, P. Human homolog of fission yeast Cdc25 mitotic inducer is predominantly expressed in G2. Proc. Natl. Acad. Sci. USA, 1990, 87(13), 5139-5143.
12. Nagata, A.; Igarashi, M.; Jinno, S.; Suto, K.; Okayama, H. An additional homolog of the fission yeast Cdc25 gene occurs in humans and is highly expressed in some cancer cells. New Biol. 1991, 3(10), 959-968.
13. Wegener, S.; Hampe, W.; Herrmann, D.; Schaller, H.C. Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur. J. Cell Biol., 2000, 79(11), 810-815.
14. Baldin, V.; Cans, C.; Superti-Furga, G.; Ducommun, B. Alternative splicing of the human CDC25B tyrosine phoshatase. Possible implications for growth control? Oncogene, 1997, 14(20), 2485-2495.
15. Forrest, A.R.; McCormack, A.K.; De Souza, C.P.; Sinnamon, J.M.; Tonks, I.D.; Hayward, N.K.; Ellem, K.A.; Gabrielli, B.G. Multiple splicing variants of Cdc25B regulate G2/M progression. Biochem. Biophys. Res. Commun., 1999, 260(2), 510-515.
16. Aressy, B.; Ducommun B. Cell Cycle Control by the CDC25 Phosphatases. Anti-Cancer Agents Med. Chem., 2008, 8(8), 818-824.
17. Bureik, M.; Rief, N.; Drescher, R.; Jungbluth, A.; Montenarh, M.; Wagner, P. An additional transcript of the cdc25C gene from A431 cells encodes a functional protein. Int. J. Oncol., 2000, 17(6), 1251-1258.
18. Ozen M, Ittmann M. Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin. Cancer Res., 2005, 11(13), 4701-4706
19. Jinno, S.; Suto, K.; Nagata, A.; Igashari, M.; Kanaoka, Y.; Nojima, H.; Okayama, H. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J., 1994, 13(7), 1549-1556.
20. Boutros, R.; Lobjois V.; Ducommun, B. CDC25 phosphatases in cancer cells:key players? Good targets? Nat. Rev. Cancer, 2007, 7(7), 495-507.
21. Rudolph, J. Cdc25 phosphatases: structure, specificity, and mechanism. Biochemistry, 2007, 46(12), 3595-3604.
22. Karlsson, C.; Katich, S.; Hagting, A.; Hoffmann, I.; Pines, J.J. Cdc25b and Cdc25c Differ Markedly in Their Properties as Initiators of Mitosis. Cell Biol., 1999, 146(3), 573-584.
23. Molinari, M.; Mercurio, C.; Dominguez, J.; Goubin, F.; Draetta, G.F. Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep., 2000, 1, 71-79.
24. Boutros, R.; Dozier, C.; Ducommun, B. The when and wheres of CDC25 phosphatases. Curr. Opin. Cell Biol., 2006, 18(2),185-191.
25. Niida, H.; Nakanishi, M. DNA damage checkpoints in mammals. Mutagenesis, 2006, 21, 3-9.
26. Kristjánsdóttir, K.; Rudolph, J. Cdc25 phosphatases and cancer. Chem. Biol., 2004, 11(8), 1043-1051.
27. Ngan, E.S.; Hashimoto, Y.; Ma, Z.Q.; Tsai, M.J.; Tsai, S.Y. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene, 2003, 22(5), 734-739.
28. Cangi, M.G.; Cukor, B.; Soung, P.; Signoretti, S.; Moreira, G. Jr.; Ranashinge, M.; Cady, B.; Pagano, M.; Loda, M. Role of the Cdc25A phosphatase in human breast cancer. J. Clin. Invest., 2000, 106(6), 753-61.
29. Wang, Z.; Trope, C.G.; Flørenes, V.A.; Suo, Z.; Nesland, J.M.; Holm, R. Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes. BMC Cancer, 2010, 10, 233.
30. Hernández, S.; Hernández, L.; Bea, S.; Pinyol, M.; Nayach, I., Bellosillo, B.; Nadal, A.; Ferrer, A.; Fernandez, P.L.; Montserrat, E.; Cardesa, A.; Campo, E. Cdc25a and the splicing variant Cdc25b2, but not Cdc25B1,-B3 or-C, are over-expressed in aggressive human non-Hodgkin's lymphomas. Int. J. Cancer, 2000, 89(2), 148-52.
31. Keyse S.M.; Ginsburg, M. Amino acid sequence similarity between CL100, a dual-specificity MAP kinase phosphatase and Cdc25. Trends Biochem. Sci., 1993, 18(10), 377-378.
32. Sohn, J.; Buhrman, G.; Rudolph, J. Kinetic and structural studies of specific protein-protein interactions in substrate catalysis by Cdc25B phosphatase. Biochemistry, 2007, 46(3), 807-818.
33. Buhrman, G.K.; Parker, B.; Sohn, J.; Rudolph, J.; Mattos, C. Structural mechanism of oxidative regulation of the phosphatase Cdc25B via an intramolecular disulfide bond. Biochemistry, 2005, 44(20), 5307-5316.
34. Fauman, E.B.; Cogswell, J.P.; Lovejoy, B.; Rocque, W.J.; Holmes, W.; Montana, V. G.; Piwnica-Worms, H.; Rink, M.J.; Saper, M.A. Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A. Cell, 1998, 93(4), 617-625.
35. Reynolds, R. A.; Yem, A. W.; Wolfe, C. L.; Deibel, M. R. Jr; Chidester, C. G.; Watenpaugh, K. D. Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle. J. Mol. Biol., 1999, 293(3), 559-68.
36. Sohn, J.; Kristjansdottir, K.A.; Safi, B.; Parker, B.; Kiburz; Rudolph, J. Remote hot spots mediate protein substrate recognition for the Cdc25 phosphatase. Proc Natl Acad Sci U S A., 2004, 101(47),16437-16441.
37. McConkey, B.J.; Sobolev, V.; Edelman, M. Quantification of protein surfaces, volumes and atom-atom contacts using a constrained Voronoi procedure. Bioinformatics, 2002, 18(10), 1365-1373.
38. Bakan, A.; Lazo J.S.; Wipf, P.; Brummond, K.M.; Bahar, I. Toward a Molecular Understanding of the Interaction of Dual Specificity Phosphatases with Substrates: Insights from Structure-Based Modeling and High Throughput Screening. Curr. Med. Chem. 2008, 15(25), 2536-2544.
39. Arantes, G.M. Flexibility and inhibitor binding in Cdc25 phosphatases. Proteins, 2010, 78(14), 3017-3032.
40. Lazo, J.S.; Aslan, D.C.; Southwick, E.C.; Cooley, K.A.; Ducruet, A.P.; Joo, B.; Vogt, A.; Wipf, P. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J. Med. Chem., 2001, 44(24), 4042-4049.
41. Sohn, J.; Kiburz, B.; Li, Z.; Deng, L.; Safi, A.; Pirrung, M.C.; Rudolph, J. Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones. J. Med. Chem., 2003, 46(13), 2580-2588.
42. Lazo, J.S.; Aslan, D.C.; Southwick, E.C.; Cooley, K.A.; Ducruet, A.P.; Joo, B.; Vogt, A.; Wipf, P. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J. Med. Chem., 2001, 44(24), 4042-4049.
43. Brault, L.; Denancé, M.; Banaszak, E.; Maadidi, S. E.; Battaglia, E.; Bagrel, D.; Samadi, M. Synthesis and biological evaluation of dialkylsubstituted maleic anhydrides as novel inhibitors of Cdc25 dual specificity phosphatases. Eur. J. Med. Chem., 2007, 42(2), 243-247.
44. Huang, W.; Li, J.; Zhang, W.; Zhou, Y.; Xie, C.; Luo, Y.; Li, Y.; Wang, J.; Li, J.; Lu, W. Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg. Med. Chem. Lett., 2006, 16(7), 1905-1908.
45. Lazo, J.S.; Nemoto, K.; Pestell, K.E.; Cooley, K.; Southwick, E.C.; Mitchell, D.A.; Furey, W.; Gussio, R.; Zaharevitz, D.W.; Joo, B.; Wipf, P. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol. Pharmacol., 2002, 61(4), 720-728.
46. Lavecchia, A.; Cosconati, S.; Limongelli, V.; Novellino, E. Modeling of Cdc25B dual specifity protein phosphatase inhibitors: docking of ligands and enzymatic inhibition mechanism. Chem. Med. Chem. 2006, 1(5), 540-550.
47. Park, H.; Bahn, Y. J.; Jung, S.-K.; Jeong, D. G.; Lee, S.-H.; Seo, I.; Yoon, T.-S.; Kim, S. J.; Ryu, S. E. Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening. J. Med. Chem. 2008, 51(18), 5533-5541.
48. Lavecchia A, Coluccia A, Di Giovanni C, Novellino E. Cdc25B phosphatase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med. Chem., 2008, 8(8), 843-856.
49. Lavecchia A, Di Giovanni C, Novellino E. CDC25A and B dualspecificity phosphatase inhibitors: potential agents for cancer therapy. Curr. Med. Chem. 2009, 16(15):1831-1849.
50. Lavecchia A, Di Giovanni C, Novellino E. Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review. Expert Opin. Ther. Pat., 2010, 20(3), 405-425.
51. Zhou, Y.B.; Feng, X.; Wang, L.N.; Du, J.Q.; Zhou, Y.Y.; Yu, H.P.; Zang, Y.; Li, J.Y.; Li, J. LGH00031, a novel ortho-quinonoid inhibitor of cell division cycle 25B, inhibits human cancer cells via ROS generation. Acta Pharmacol. Sin., 2009, 30(9):1359-1368.
52. Park, H.;. Bahn, Y.J.; Ryu, S.E. Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(15), 4330-4334.
53. Park, H.; Bahn, Y. J.; Jung, S.-K.; Jeong, D. G.; Lee, S.-H.; Seo, I.; Yoon, T.-S.; Kim, S. J.; Ryu, S. E. Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening. J. Med. Chem., 2008, 51(18), 5533-5541.
54. Montes, M.; Braud, E.; Miteva, M.A.; Goddard, M.L.; Mondésert, O.; Kolb, S.; Brun, M.P.; Ducommun, B.; Garbay, C.; Villoutreix, B.O. J. Receptor-based virtual ligand screening for the identification of novel CDC25 phosphatase inhibitors. Chem. Inf. Model. 2008, 48(1), 157-165.
55. Kolb, S.; Mondesert, O.; Goddard, M. L.; Jullien, D.; Villoutreix, B. O.; Ducommun, B.; Garbay, C.; Braud, E Development of novel thiazolopyrimidines as CDC25B phosphatase inhibitors. Chem. Med. Chem. 2009, 4(4), 633-648.
56. Duval, R.; Kolb, S.; Braud, E.; Genest, D.; Garbay, C. Rapid Discovery of Triazolobenzylidene-Thiazolopyrimidines (TBTP) as CDC25 Phosphatase Inhibitors by Parallel Click Chemistry and in Situ screening. J. Comb. Chem., 2009, 11(6), 947-950.
57. Valente, S.; Bana, E.; Viry, E.; Bagrel, D.; Kirsch, G. Synthesis and biological evaluation of novel coumarin-based inhibitors of Cdc25 phosphatases. Bioorg. Med. Chem. Lett., 2010, 20(19), 5827-5830.
58. Deep, G.; Oberlies, N. H.; Kroll, D. J.; Agarwal, R. Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. Int. J. Cancer, 2008, 123(1), 41-50.
59. Johnston, P.A.; Foster, C.A.; Tierno, M.B.; Shun, T.Y.; Shinde, S.N.; Paquette, W.D.; Brummond, K.M.; Wipf, P.; Lazo, J.S. Cdc25B Dual-Specificity Phosphatase Inhibitors Identified in a High-Throughput Screen of the NIH Compound Library. Assay Drug. Dev. Technol., 2009, 7(3), 250-265.
60. Chen, H.J.; Liu, Y.; Wang, L.N.; Shen, Q.; Li, J.; Nan, F.J. Discovery and structural optimization of pyrazole derivatives as novel inhibitors of Cdc25B. Bioorg. Med. Chem. Lett., 2010, 20(9), 2876-2879.
61. Wardman, P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr. Med. Chem., 2001, 8(7) 739-761.
62. Nishikawa, Y.; Carr, B. I.; Wang, M.; Kar, S.; Finn, F.; Dowd, P.; Zheng, Z. B.; Kerns, J.; Naganathan, S. J. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. J. Biol. Chem., 1995, 270(47), 28304-28310.
63. Ham, S. W.; Choe, J. I.; Wang, M. F.; Peyregne, V.; Carr, B. I. Fluorinated quinoid inhibitor: possible "pure" arylator predicted by the simple theoretical calculation. Bioorg. Med. Chem. Lett. 2004, 14(15), 4103-4105.
64. Kar, S.; Wang, M.; Ham, S. W.; Carr, B. I. Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK. Biochem. Pharmacol., 2006, 72(10), 1217-1227.
65. Park, H.; Carr, B. I.; Li, M.; Ham, S. W. Fluorinated NSC as a Cdc25 inhibitor. Bioorg. Med. Chem. Lett., 2007, 17(8), 2351-2354.-2354
66. Zakharova, O.D.; Ovchinnikova, L.P.; Goryunov, L.I.; Troshkova, N.M.; Shteingarts, V.D.; Nevinsky, G.A. Cytotoxicity of new alkylamino-and phenylamino-containing polyfluorinated derivatives of 1,4-naphthoquinone. Eur. J. Med. Chem., 2010, 45(6), 2321-2326.
67. Zakharova, O.D.; Ovchinnikova, L.P.; Goryunov, L.I.; Troshkova, N.M.; Shteingarts, V.D.; Nevinsky, G.A. Cytotoxicity of new nbutylamino and sulfur-containing derivatives of polyfluorinated 1,4-naphthoquinone. Eur. J. Med. Chem., 2010, 45(1), 270-274.
68. Zakharova, O.D.; Ovchinnikova, L.P.; Goryunov, L.I.; Troshkova, N.M.; Shteingarts, V.D.; Nevinsky, G.A. Cytotoxicity of new polyfluorinated 1,4-naphtoquinones with diverse substituents in the quinone moiety. Bioorg. Med. Chem., 2011, 19(1), 256-260.
69. Nussbaum, F.; Ebbinghaus A.; Mayer-Bartschmid, A.; Zitzmann, W.; Wiese W.B.; Stadler M.; Anlauf, S. CDC25 inhibitors. E. P. Patent 2, 130, 831, December 09, 2009.
70. Omura S.; Tanaka, H.; Tsuzuki, K.; Murata, Y. Antibiotic Diazaquionomycin a derivative. Jp. Patent, 6,307,983,0, April 09, 1988.
71. Avendano, C.;. Alonso, M. A.; Espada, M.; Garcia Gravalos, D.; Antitumoral aza-and diazaanthracenes. E. P. Patent 0, 574, 195, December 15, 1993.
72. Avendano Lopez C.; Garcia Gravalos, D. Anthraquinonic derivatives having an antitumor activity and applications thereof. U.S. Patent 5,716,963, February 10, 1998.
73. Prevost, G.; Liberatore, A.M.; Bigg, D.; Pons, D. Triaminopyrimidine derivatives as inhibitors of CDC25 phosphatase. U.S. Patent 0, 137, 275, March 06, 2010.
74. Liberatore, A.M.; Pons, D.; Bigg, D.; Prevost, G.; Brezak Pannetier, M.C. Triaminopyrimidine cyclobutenedione derivatives used as phosphatase CDC25 inhibitors. U.S. Patent 0,173,910, August 07, 2010.
75. Goubin-Gramatica, F.; Ducommun, B.; Prevost, G.; Method for obtaining human CDC25 phosphatases and method for identifying human CDC25 phosphatase modulators. W.O. Patent 0, 144, 467, June 21, 2001.
76. Liberatore, A.M.; Prevost, G. Auvin, S.; Brehu, L.; Triaminopyrimidine derivatives as CDC25 phosphatase inhibitors. W.O. Patent 1, 309, 00, November 18, 2010.
77. Contour-Galcera, M.O.; Sidhu, A.; Prévost, G.; Bigg, D.; Ducommun, B. What's new on CDC25 phosphatase inhibitors. Pharmacol. Ther., 2006, 115(1), 1-12.
78. Jiang, Z.X.; Zhang, Z.Y. Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev., 2008, 27(2), 263-272.
79. Sohn, J.; Parks, J.M.; Buhrman, G.; Brown, P.; Kristjánsdóttir, K.; Safi A.; Edelsbrunner, H.; Yang, W.; Rudolph, J. Experimental validation of the docking orientation of Cdc25 with its Cdk2-CycA protein substrate. Biochemistry, 2005, 44(50), 16563-16573.
80. Brisson, M.; Nguyen, T.; Wipf, P.; Joo, B.; Day, B.W.; Skoko, J.S.; Schreiber, E.M.; Foster, C.; Bansal, P.; Lazo, J.S. Redox regulation of Cdc25B by cell-active quinolinediones. Mol Pharmacol., 2005, 68(6),1810-1820.
81. Brisson, M.; Foster, C.; Wipf, P.; Joo, B.; Tomko, R.J. Jr.; Nguyen, T.; Lazo, J.S. Independent mechanistic inhibition of cdc25 phosphatases by a natural product caulibugulone. Mol. Pharmacol. 2007, 71(1), 184-192.
82. Keinan, S.; Paquette, W.D.; Skoko, J.J.; Beratan, D.N.; Yang, W.; Shinde, S.; Johnston, P.A.; Lazo J.S.; Wipf, P. Computational design, synthesis and biological evaluation of para-quinone based inhibitors for redox regulation of the dual-specificity phosphatase Cdc25B. Org. Biomol. Chem., 2008, 6(18), 3256-3263.